• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
[Mechanisms and countermeasures in relapse of relapsed/refractory non-Hodgkin lymphoma after treatment of CD19 chimeric antigen receptor T cells].[CD19嵌合抗原受体T细胞治疗后复发/难治性非霍奇金淋巴瘤复发的机制及对策]
Zhonghua Xue Ye Xue Za Zhi. 2020 May 14;41(5):437-440. doi: 10.3760/cma.j.issn.0253-2727.2020.05.017.
2
Efficacy and toxicity for CD22/CD19 chimeric antigen receptor T-cell therapy in patients with relapsed/refractory aggressive B-cell lymphoma involving the gastrointestinal tract.CD22/CD19 嵌合抗原受体 T 细胞疗法治疗累及胃肠道的复发/难治性侵袭性 B 细胞淋巴瘤患者的疗效和毒性。
Cytotherapy. 2020 Mar;22(3):166-171. doi: 10.1016/j.jcyt.2020.01.008. Epub 2020 Feb 13.
3
Anti-CD19 chimeric antigen receptors T cells for the treatment of relapsed or refractory E2A-PBX1 positive acute lymphoblastic leukemia: report of three cases.抗 CD19 嵌合抗原受体 T 细胞治疗复发或难治性 E2A-PBX1 阳性急性淋巴细胞白血病：三例报告。
Leuk Lymphoma. 2019 Jun;60(6):1454-1461. doi: 10.1080/10428194.2018.1533127. Epub 2019 Feb 4.
4
Chimeric antigen receptor T-cell therapy for the treatment of aggressive B-cell non-Hodgkin lymphomas: efficacy, toxicity, and comparative chimeric antigen receptor products.嵌合抗原受体 T 细胞疗法治疗侵袭性 B 细胞非霍奇金淋巴瘤：疗效、毒性和比较嵌合抗原受体产品。
Expert Opin Biol Ther. 2019 Nov;19(11):1157-1164. doi: 10.1080/14712598.2019.1644316. Epub 2019 Jul 25.
5
Chimeric antigen receptor modified T cell therapy in B cell non-Hodgkin lymphomas.嵌合抗原受体修饰 T 细胞疗法治疗 B 细胞非霍奇金淋巴瘤。
Am J Hematol. 2019 May;94(S1):S18-S23. doi: 10.1002/ajh.25403. Epub 2019 Jan 24.
6
Axicabtagene Ciloleucel CAR T-cell therapy for relapsed/refractory secondary CNS non-Hodgkin lymphoma: comparable outcomes and toxicities, but shorter remissions may warrant alternative consolidative strategies?阿基仑赛 CAR T 细胞疗法治疗复发/难治性继发性中枢神经系统非霍奇金淋巴瘤：疗效和毒性相当，但缓解期较短可能需要替代巩固策略？
Bone Marrow Transplant. 2021 Apr;56(4):974-977. doi: 10.1038/s41409-020-01099-4. Epub 2020 Nov 10.
7
[Efficacy and safety of CD19 chimeric antigen receptor T cells for the treatment of 22 patients with B-cell lymphoma].CD19嵌合抗原受体T细胞治疗22例B细胞淋巴瘤的疗效与安全性
Zhonghua Xue Ye Xue Za Zhi. 2019 Apr 14;40(4):276-280. doi: 10.3760/cma.j.issn.0253-2727.2019.04.003.
8
Chimeric Antigen Receptor-Engineered T Cell Therapy in Lymphoma.嵌合抗原受体修饰 T 细胞治疗淋巴瘤。
Curr Oncol Rep. 2019 Mar 27;21(5):38. doi: 10.1007/s11912-019-0789-z.
9
In Vivo Fate and Activity of Second- versus Third-Generation CD19-Specific CAR-T Cells in B Cell Non-Hodgkin's Lymphomas.体内第二代与第三代 CD19 特异性 CAR-T 细胞在 B 细胞非霍奇金淋巴瘤中的命运和活性。
Mol Ther. 2018 Dec 5;26(12):2727-2737. doi: 10.1016/j.ymthe.2018.09.009. Epub 2018 Sep 13.
10
Mechanisms of failure of chimeric antigen receptor T-cell therapy.嵌合抗原受体 T 细胞疗法失败的机制。
Curr Opin Hematol. 2019 Nov;26(6):427-433. doi: 10.1097/MOH.0000000000000548.

本文引用的文献

1
Anti-CD19 CAR T-Cell Therapy for B-Cell Non-Hodgkin Lymphoma.抗 CD19 CAR T 细胞疗法治疗 B 细胞非霍奇金淋巴瘤。
Transfus Med Rev. 2020 Jan;34(1):29-33. doi: 10.1016/j.tmrv.2019.08.003. Epub 2019 Aug 29.
2
Anti-CD19 Chimeric Antigen Receptor T Cells in Combination With Nivolumab Are Safe and Effective Against Relapsed/Refractory B-Cell Non-hodgkin Lymphoma.抗CD19嵌合抗原受体T细胞联合纳武单抗治疗复发/难治性B细胞非霍奇金淋巴瘤安全有效。
Front Oncol. 2019 Aug 19;9:767. doi: 10.3389/fonc.2019.00767. eCollection 2019.
3
Clinical Efficacy and Tumor Microenvironment Influence in a Dose-Escalation Study of Anti-CD19 Chimeric Antigen Receptor T Cells in Refractory B-Cell Non-Hodgkin's Lymphoma.在一项抗 CD19 嵌合抗原受体 T 细胞治疗难治性 B 细胞非霍奇金淋巴瘤的剂量递增研究中的临床疗效和肿瘤微环境影响。
Clin Cancer Res. 2019 Dec 1;25(23):6995-7003. doi: 10.1158/1078-0432.CCR-19-0101. Epub 2019 Aug 23.
4
Chimeric Antigen Receptor T Cells Targeting CD79b Show Efficacy in Lymphoma with or without Cotargeting CD19.嵌合抗原受体 T 细胞靶向 CD79b 在伴有或不伴有共靶向 CD19 的淋巴瘤中显示疗效。
Clin Cancer Res. 2019 Dec 1;25(23):7046-7057. doi: 10.1158/1078-0432.CCR-19-1337. Epub 2019 Aug 22.
5
Enhancing CAR T-cell therapy through cellular imaging and radiotherapy.通过细胞成像和放射疗法增强 CAR T 细胞疗法。
Lancet Oncol. 2019 Aug;20(8):e443-e451. doi: 10.1016/S1470-2045(19)30461-9. Epub 2019 Jul 29.
6
Rapid relapse of large B-cell lymphoma after CD19 directed CAR-T-cell therapy due to CD-19 antigen loss.由于CD-19抗原丢失，CD19导向的嵌合抗原受体T细胞（CAR-T）疗法治疗后大B细胞淋巴瘤快速复发。
Am J Hematol. 2019 Oct;94(10):E273-E275. doi: 10.1002/ajh.25591. Epub 2019 Aug 13.
7
Radiation Priming Chimeric Antigen Receptor T-Cell Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma With High Tumor Burden.高肿瘤负荷复发/难治性弥漫性大 B 细胞淋巴瘤的放射致敏嵌合抗原受体 T 细胞治疗。
J Immunother. 2020 Jan;43(1):32-37. doi: 10.1097/CJI.0000000000000284.
8
Chimeric Antigen Receptor T-Cell Therapies for Aggressive B-Cell Lymphomas: Current and Future State of the Art.用于侵袭性B细胞淋巴瘤的嵌合抗原受体T细胞疗法：当前与未来的技术水平
Am Soc Clin Oncol Educ Book. 2019 Jan;39:446-453. doi: 10.1200/EDBK_238693. Epub 2019 May 17.
9
CD40 Ligand-Modified Chimeric Antigen Receptor T Cells Enhance Antitumor Function by Eliciting an Endogenous Antitumor Response.CD40 配体修饰的嵌合抗原受体 T 细胞通过引发内源性抗肿瘤反应增强抗肿瘤功能。
Cancer Cell. 2019 Mar 18;35(3):473-488.e6. doi: 10.1016/j.ccell.2019.02.006.
10
Preclinical Development of Bivalent Chimeric Antigen Receptors Targeting Both CD19 and CD22.靶向CD19和CD22的双价嵌合抗原受体的临床前开发
Mol Ther Oncolytics. 2018 Nov 6;11:127-137. doi: 10.1016/j.omto.2018.10.006. eCollection 2018 Dec 21.

[Mechanisms and countermeasures in relapse of relapsed/refractory non-Hodgkin lymphoma after treatment of CD19 chimeric antigen receptor T cells].

作者信息

Wang S Y, Cao J, Xu K L

机构信息

Department of Hematology, The Affiliated Hospital of Xuzhou Medical University, Xuzhou 221002, China.

出版信息

Zhonghua Xue Ye Xue Za Zhi. 2020 May 14;41(5):437-440. doi: 10.3760/cma.j.issn.0253-2727.2020.05.017.

DOI:10.3760/cma.j.issn.0253-2727.2020.05.017
PMID:32536147
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7342074/
Abstract
摘要